Biotechnology
Filter News
Found 11,878 articles
-
DURECT Corporation to Participate in the Berenberg NASH Day
2/21/2019
DURECT Corporation today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg's New York City offices.
-
Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call
2/21/2019
Spectrum Pharmaceuticals, announced it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
2/21/2019
Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments
-
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
2/21/2019
Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, announced the appointment of Rachelle Jacques as Chief Executive Officer.
-
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
2/21/2019
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 8th Annual Global Healthcare Conference in New York.
-
Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.
2/21/2019
Anixa Biosciences, Inc. announced it has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.
-
Grace Therapeutics to Present at the Cowen 39th Annual Healthcare Conference
2/21/2019
Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced that it is scheduled to speak at the Cowen Healthcare Conference in Boston.
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
2/21/2019
Aimmune Therapeutics, Inc. announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
-
First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension
2/21/2019
Complexa Inc. announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension.
-
Rebirth of a Heart Valve: Franciscan Health Surgeon First in World to Use Device
2/21/2019
Clinical Trial Tests Advanced Application of an ECM® Cardiac Valve at Heart Center
-
Base Pair Biotechnologies Announces Fast Track SBIR Grant Award from National Institutes of Health
2/21/2019
Base Pair Biotechnologies, Inc., the Aptamer Discovery Company™, announced today the receipt of a Fast Track Small Business Innovation Research grant from the National Institute on Drug Abuse of the National Institutes of Health.
-
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
2/21/2019
Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research
-
bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
2/21/2019
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
-
AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial
2/21/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial.
-
Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
2/21/2019
Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.
-
Progenity Announces Expansion of Board of Directors
2/21/2019
Company Focused on Diagnostic and Therapeutic Precision Medicine Solutions in Prenatal and Perinatal Healthcare, Oncology, and Gastroenterology
-
Vertex Appoints Lloyd Carney to its Board of Directors
2/21/2019
Vertex Pharmaceuticals Incorporated announced that Lloyd Carney has been appointed to its board of directors as an independent director.
-
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
2/21/2019
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York.
-
Halozyme Reports Fourth Quarter And Full-Year 2018 Results
2/21/2019
ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million
-
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
2/21/2019
Array BioPharma Inc. announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York.